Búsqueda | Portal de Búsqueda de la BVS España

1.

International multidisciplinary expert panel consensus on breast reconstruction and radiotherapy.

Nava, M B; Benson, J R; Audretsch, W; Blondeel, P; Catanuto, G; Clemens, M W; Cordeiro, P G; De Vita, R; Hammond, D C; Jassem, J; Lozza, L; Orecchia, R; Pusic, A L; Rancati, A; Rezai, M; Scaperrotta, G; Spano, A; Winters, Z E; Rocco, N.

Br J Surg; 106(10): 1327-1340, 2019 09.

Artículo en Inglés | MEDLINE | ID: mdl-31318456

2.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang, M C U; Bliss, J M; Viale, G; Speirs, V; Palmieri, C; Shaaban, A; Lønning, P E; Morden, J; Porta, N; Jassem, J; van De Velde, C J; Rasmussen, B B; Verhoeven, D; Bartlett, J M S; Coombes, R C.

Breast Cancer Res Treat; 168(1): 169-178, 2018 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-29177605

3.

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.

Tomasik, B; Bienkowski, M; Jassem, J.

Ann Oncol; 33(6): 658-659, 2022 06.

Artículo en Inglés | MEDLINE | ID: mdl-35306157

4.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Dubsky, P; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H-J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J; Denkert, C; Di Leo, A; Ejlertsen, B; Francis, P; Galimberti, V; Garber, J; Gulluoglu, B; Goodwin, P; Harbeck, N; Hayes, D F; Huang, C-S; Huober, J; Hussein, K; Jassem, J; Jiang, Z; Karlsson, P; Morrow, M; Orecchia, R; Osborne, K C; Pagani, O; Partridge, A H; Pritchard, K; Ro, J; Rutgers, E J T; Sedlmayer, F; Semiglazov, V; Shao, Z; Smith, I; Toi, M; Tutt, A.

Ann Oncol; 28(8): 1700-1712, 2017 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-28838210

5.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

Scagliotti, G V; Bondarenko, I; Blackhall, F; Barlesi, F; Hsia, T-C; Jassem, J; Milanowski, J; Popat, S; Sanchez-Torres, J M; Novello, S; Benner, R J; Green, S; Molpus, K; Soria, J-C; Shepherd, F A.

Ann Oncol; 26(3): 497-504, 2015 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-25395283

6.

Prognostic and predictive value of ERß1 and ERß2 in the Intergroup Exemestane Study (IES)-first results from PathIES.

Speirs, V; Viale, G; Mousa, K; Palmieri, C; Reed, S N; Nicholas, H; Cheang, M; Jassem, J; Lønning, P E; Kalaitzaki, E; van de Velde, C J H; Rasmussen, B B; Verhoeven, D M; Shaaban, A M; Bartlett, J M S; Bliss, J M; Coombes, R C.

Ann Oncol; 26(9): 1890-1897, 2015 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-26002610

7.

Prognostic value of microRNA expression in operable non-small cell lung cancer patients.

Skrzypski, M; Czapiewski, P; Goryca, K; Jassem, E; Wyrwicz, L; Pawlowski, R; Rzyman, W; Biernat, W; Jassem, J.

Br J Cancer; 110(4): 991-1000, 2014 Feb 18.

Artículo en Inglés | MEDLINE | ID: mdl-24448358

8.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Bonnefoi, H; Litière, S; Piccart, M; MacGrogan, G; Fumoleau, P; Brain, E; Petit, T; Rouanet, P; Jassem, J; Moldovan, C; Bodmer, A; Zaman, K; Cufer, T; Campone, M; Luporsi, E; Malmström, P; Werutsky, G; Bogaerts, J; Bergh, J; Cameron, D A.

Ann Oncol; 25(6): 1128-36, 2014 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-24618153

9.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Douillard, J Y; Siena, S; Cassidy, J; Tabernero, J; Burkes, R; Barugel, M; Humblet, Y; Bodoky, G; Cunningham, D; Jassem, J; Rivera, F; Kocákova, I; Ruff, P; Blasinska-Morawiec, M; Smakal, M; Canon, J L; Rother, M; Oliner, K S; Tian, Y; Xu, F; Sidhu, R.

Ann Oncol; 25(7): 1346-1355, 2014 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-24718886

10.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky, P; Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H-J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J; Denkert, C; Di Leo, A; Ejlertsen, B; Francis, P; Galimberti, V; Garber, J; Gulluoglu, B; Goodwin, P; Harbeck, N; Hayes, D F; Huang, C-S; Huober, J; Khaled, H; Jassem, J; Jiang, Z; Karlsson, P; Morrow, M; Orecchia, R; Osborne, K C; Pagani, O; Partridge, A H; Pritchard, K; Ro, J; Rutgers, E J T; Sedlmayer, F; Semiglazov, V; Shao, Z; Smith, I; Toi, M; Tutt, A.

Ann Oncol; 29(1): 281-282, 2018 01 01.

Artículo en Inglés | MEDLINE | ID: mdl-29045519

11.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano, G; Burstein, H J; Winer, E P; Gnant, M; Dubsky, P; Loibl, S; Colleoni, M; Regan, M M; Piccart-Gebhart, M; Senn, H-J; Thürlimann, B; André, F; Baselga, J; Bergh, J; Bonnefoi, H; Brucker, S Y; Cardoso, F; Carey, L; Ciruelos, E; Cuzick, J; Denkert, C; Di Leo, A; Ejlertsen, B; Francis, P; Galimberti, V; Garber, J; Gulluoglu, B; Goodwin, P; Harbeck, N; Hayes, D F; Huang, C-S; Huober, J; Khaled, H; Jassem, J; Jiang, Z; Karlsson, P; Morrow, M; Orecchia, R; Osborne, K C; Pagani, O; Partridge, A H; Pritchard, K; Ro, J; Rutgers, E J T; Sedlmayer, F; Semiglazov, V; Shao, Z; Smith, I; Toi, M; Tutt, A.

Ann Oncol; 29(10): 2153, 2018 Oct 01.

Artículo en Inglés | MEDLINE | ID: mdl-29733336

12.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.

Minuti, G; Cappuzzo, F; Duchnowska, R; Jassem, J; Fabi, A; O'Brien, T; Mendoza, A D; Landi, L; Biernat, W; Czartoryska-Arlukowicz, B; Jankowski, T; Zuziak, D; Zok, J; Szostakiewicz, B; Foszczynska-Kloda, M; Tempinska-Szalach, A; Rossi, E; Varella-Garcia, M.

Br J Cancer; 107(5): 793-9, 2012 Aug 21.

Artículo en Inglés | MEDLINE | ID: mdl-22850551

13.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

Dziadziuszko, R; Jassem, J.

Ann Oncol; 23 Suppl 10: x193-6, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22987961

14.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

Brodowicz, T; Ciuleanu, T; Crawford, J; Filipits, M; Fischer, J R; Georgoulias, V; Gridelli, C; Hirsch, F R; Jassem, J; Kosmidis, P; Krzakowski, M; Manegold, Ch; Pujol, J L; Stahel, R; Thatcher, N; Vansteenkiste, J; Minichsdorfer, C; Zöchbauer-Müller, S; Pirker, R; Zielinski, C C.

Ann Oncol; 23(5): 1223-1229, 2012 May.

Artículo en Inglés | MEDLINE | ID: mdl-21940784

15.

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

Manegold, C; van Zandwijk, N; Szczesna, A; Zatloukal, P; Au, J S K; Blasinska-Morawiec, M; Serwatowski, P; Krzakowski, M; Jassem, J; Tan, E H; Benner, R J; Ingrosso, A; Meech, S J; Readett, D; Thatcher, N.

Ann Oncol; 23(1): 72-77, 2012 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-21464154

16.

Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict.

Van Hemelrijck, M; Fox, L; Beyer, K; Fedaraviciute, E; George, G; Hadi, H; Haire, A; Handford, J; Mera, A; Monroy-Iglesias, M J; Moss, C L; Perdek, N; Russell, B; Santaolalla, A; Sztankay, M; Wylie, H; Jassem, J; Zubaryev, M; Anderson, B O; Ortiz, R; Ilbawi, A; Camacho, R; Ferreira-Borges, C; Roitberg, F; Dvaladze, A E; Lasierra Losada, M; Alves da Costa, F; Aggarwal, A; Lawler, M; Kopetskiy, S; Sullivan, R.

J Cancer Policy; 34: 100370, 2022 12.

Artículo en Inglés | MEDLINE | ID: mdl-36375808

17.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Bertelli, G; Hall, E; Ireland, E; Snowdon, C F; Jassem, J; Drosik, K; Karnicka-Mlodkowska, H; Coombes, R C; Bliss, J M.

Ann Oncol; 21(3): 498-505, 2010 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-19717534

18.

Third consensus on medical treatment of metastatic breast cancer.

Beslija, S; Bonneterre, J; Burstein, H J; Cocquyt, V; Gnant, M; Heinemann, V; Jassem, J; Köstler, W J; Krainer, M; Menard, S; Petit, T; Petruzelka, L; Possinger, K; Schmid, P; Stadtmauer, E; Stockler, M; Van Belle, S; Vogel, C; Wilcken, N; Wiltschke, C; Zielinski, C C; Zwierzina, H.

Ann Oncol; 20(11): 1771-85, 2009 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-19608616

19.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes, R C; Kilburn, L S; Snowdon, C F; Paridaens, R; Coleman, R E; Jones, S E; Jassem, J; Van de Velde, C J H; Delozier, T; Alvarez, I; Del Mastro, L; Ortmann, O; Diedrich, K; Coates, A S; Bajetta, E; Holmberg, S B; Dodwell, D; Mickiewicz, E; Andersen, J; Lønning, P E; Cocconi, G; Forbes, J; Castiglione, M; Stuart, N; Stewart, A; Fallowfield, L J; Bertelli, G; Hall, E; Bogle, R G; Carpentieri, M; Colajori, E; Subar, M; Ireland, E; Bliss, J M.

Lancet; 369(9561): 559-70, 2007 Feb 17.

Artículo en Inglés | MEDLINE | ID: mdl-17307102

20.

Parallel-opposed fields versus four fields, and two- versus three-dimensional radiotherapy planning in thin patients with gynecological malignancies.

Bednaruk-Mlynski, E; Senkus-Konefka, E; Szewczyk, P; Badzio, A; Jassem, J.

Neoplasma; 55(2): 151-7, 2008.

Artículo en Inglés | MEDLINE | ID: mdl-18237254

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

International multidisciplinary expert panel consensus on breast reconstruction and radiotherapy.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

Prognostic and predictive value of ERß1 and ERß2 in the Intergroup Exemestane Study (IES)-first results from PathIES.

Prognostic value of microRNA expression in operable non-small cell lung cancer patients.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.

Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.

Third consensus on medical treatment of metastatic breast cancer.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Parallel-opposed fields versus four fields, and two- versus three-dimensional radiotherapy planning in thin patients with gynecological malignancies.